河南羚锐制药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600285 证券简称：羚锐制药 公告编号：2023-049 重要内容提示： 会议召开时间：2023 年 11 月 15 日(星期三) 下午 15:00-16:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 08 日(星期三) 至 11 月 14 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600285@lingrui.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南羚锐制药股份有限公司（以下简称"公司"）已于 2023 年 10 月 28 日发 布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、 ...

关于股东权益变动超过 1%的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动后，新县鑫源贸易有限公司（以下简称"鑫源贸易"）及 其一致行动人合计持有的河南羚锐制药股份有限公司（以下简称"公司"）股份 比例由 25.78%变动至 24.45%。 本次权益变动不会导致公司实际控制人发生变化，不会对公司治理结构 及未来持续经营产生影响。 证券代码：600285 证券简称：羚锐制药 公告编号：2023-048 号 河南羚锐制药股份有限公司 3、本次变动不存在违反《证券法》《上市公司收购管理办法》等法律法规和上海证券交易 所业务规则等相关规定及相关承诺的情形。 二、本次权益变动前后，公司实际控制人及其一致行动人拥有上市公司权益的 股份变动情况 | 股东名称 | 本次权益变动前持有股份 | | 本次权益变动后持有股份 | | | --- | --- | --- | --- | --- | | | 股数（股） | 占总股本 | 股数（股） | 占总股本 | | | | 比例 | | 比例 | | ...

证券代码：600285 证券简称：羚锐制药 公告编号：2023-047 号 河南羚锐制药股份有限公司 关于参与认购私募投资基金份额的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基金概述 河南羚锐制药股份有限公司（以下简称"公司"）于 2023 年 7 月 24 日召开 第九届董事会第三次会议，审议通过《关于参与认购私募基金份额的议案》，同 意公司作为有限合伙人出资 10,000 万元认购厦门金镒兴股权投资基金合伙企业 （有限合伙）（以下简称"金镒兴"或者"基金"）的份额。具体内容详见公司 于 2023 年 7 月 25 日在上海证券交易所网站（www.sse.com.cn）披露的《羚锐制 药关于参与认购私募基金份额的公告》（公告编号：2023-041）。 二、基金备案情况 近日，公司收到金镒兴通知，金镒兴已在中国证券投资基金业协会完成备案 手续，备案信息如下： 基金名称：厦门金镒兴股权投资基金合伙企业（有限合伙） 管理人名称：金镒（珠海）股权投资管理有限公司 托管人名称：兴业银行股份有限公司 备案编码：SB7 ...

证券代码：600285 证券简称：羚锐制药 公告编号： 2023-046 号 河南羚锐制药股份有限公司 关于大股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 河南羚锐集团有限公司（以下简称"羚锐集团"）持有河南羚锐制药股份 有限公司（以下简称"公司"）股份 121,817,898 股，占公司总股本的 21.48%。 本次质押 5,500,000 股后，羚锐集团累计质押公司股份 56,254,148 股，占其所 持公司股份数的 46.18%，占公司总股本的 9.92%。 截至本公告披露日，羚锐集团及其一致行动人累计质押公司股份 65,854,148 股，占公司总股本的 11.61%。 一、本次股份质押基本情况 近日，公司接到羚锐集团股份质押的通知，羚锐集团将持有公司无限售流通 股 5,500,000 股质押给华夏银行股份有限公司郑州分行，具体如下。 2.质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障 1 用途。 3.股东累计质押股份情况 截至公告披露日，上述股东及其一致行动 ...

回购注销部分限制性股票实施之法律意见书 致:河南羚锐制药股份有限公司 北京金台（武汉）律师事务所（以下简称"本所"）接受河南羚锐制药股份有限 公司 (以下简称"羚锐制药"或"公司") 委托, 担任公司 2021 年限制性股票激励计 划(以下简称"本次激励计划")的专项法律顾问。本所律师根据《中华人民共和国 公司法》(以下简称"《公司法》")《中华人民共和国证券法》(以下简称"《证券法》"、 中国证券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司股权激励管 理办法》(以下简称"《管理办法》") 等我国现行法律、法规和规范性文件以及《河南 羚锐制药股份有限公司章程》(以下简称"《公司章程》")《河南羚锐制药股份有限公 司 2021 年限制性股票激励计划（草案 》(以下简称"《激励计划(草案)》"的有关 规定，已就公司回购注销部分限制性股票（以下简称"本次回购注销"）出具了《北 京金台（武汉）律师事务所关于河南羚锐制药股份有限公司 2021 年限制性股票激励 计划第二期解锁条件成就及回购注销部分限制性股票之专项法律意见书》(以下简称 "《回购注销法律意见书》")，现就公司本次回购注销部分限制性股票实施（以 ...

（一）2023 年 6 月 20 日，公司第九届董事会第二次会议及第九届监事会第 二次会议审议通过了《关于回购注销部分限制性股票及调整回购价格的议案》， 具体内容详见公司于 2023 年 6 月 21 日在上海证券交易所网站（www.sse.com.cn） 和指定信息披露媒体披露的相关公告。 证券简称：羚锐制药 证券代码： 600285 公告编号： 2023-045 号 河南羚锐制药股份有限公司 关于部分股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：河南羚锐制药股份有限公司（以下简称"公司"）2021 年 限制性股票激励计划 2 名激励对象离职及 14 名激励对象 2022 年度考核未达到 100%解除限售条件，公司拟对其已获授但尚未解除限售的 155,688 股限制性股票 予以回购注销。 本次注销股份的有关情况 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | | | | --- | --- | --- | --- | -- ...

Financial Performance - The total comprehensive income for the period decreased by ¥1,949,442.88, resulting in a total of ¥268,680,235.65[56] - The total comprehensive income for the period was -186,542.77, with a total of 316,981,106.19 for the previous period[69] - The company reported a profit distribution of -338,456,013.00, indicating a significant loss allocation to shareholders[69] - The total assets at the end of the period amounted to 2,292,014,998.21, reflecting a stable financial position[73] - The total equity attributable to shareholders was approximately 2.55 billion, reflecting a decrease of about 0.3% compared to the previous period[194] - The company reported a decrease in retained earnings of ¥282,126,333.50 during the reporting period[56] - The company’s retained earnings decreased by approximately 21.47 million during the current period[194] - The company evaluated its ability to continue as a going concern and found no significant doubts regarding its operational viability[79] Assets and Liabilities - The company's non-current liabilities due within one year decreased by 79.85% to CNY 245,423.53 from CNY 1,218,259.37, primarily due to a reduction in lease liabilities[1] - Other current liabilities decreased by 45.72% to CNY 27,559,188.52 from CNY 50,770,352.58, mainly due to a reduction in pending sales tax[1] - The total liabilities for the current period were approximately 1.72 billion, showing a slight increase from 1.71 billion[192] - The company reported a decrease in contract liabilities from approximately 153.75 million to 51.70 million, a decline of about 66.4%[192] - The company’s deferred income tax assets increased to approximately 182.97 million from 158.96 million, an increase of about 15.1%[192] - The company’s other non-current assets rose to approximately 502.22 million from 366.56 million, an increase of about 37.0%[192] Shareholder Information - The company reported a total of 121,817,898 shares held by Henan Lingrui Group, accounting for 21.47% of total shares, with 65,257,148 shares pledged[35] - The top ten unrestricted shareholders hold a total of 121,817,898 shares, representing a significant portion of the company's equity[36] - The number of restricted shares held by equity incentive objects is 1,050,000, with the restriction lifting on July 31, 2023, and July 29, 2024[37] - The number of common shareholders at the end of the reporting period was 28,843[194] Environmental Commitment - The company emphasizes its commitment to environmental protection and has been recognized as a national-level "Green Factory"[42] - The company has completed the application for the renewal of its pollutant discharge permit and has met the requirements for self-monitoring of environmental impact[21] - The company has adopted advanced technology and management practices to minimize pollution and ensure compliance with environmental regulations[20] - The company has implemented measures to reduce water consumption and energy usage, achieving further reductions in resource consumption[43] - The company has a robust emergency response system for environmental incidents, with annual drills conducted to enhance preparedness[42] Research and Development - The company will continue to strengthen R&D talent recruitment and focus on targeted research and development investments in its existing advantageous fields[10] - The company is investing in R&D, with a budget increase of 25% for new technology development[197] Market Outlook - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 15%[197] - User data indicates a rise in active users by 20% compared to the previous year, reaching a total of 1.2 million users[197] - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[197] - New product launches are expected to contribute an additional 5% to overall revenue in the upcoming quarters[197] - Market expansion plans include entering two new international markets by the end of 2023[197] - The company is considering strategic acquisitions to enhance its product portfolio and market presence[197] Financial Reporting and Compliance - The financial statements comply with accounting standards, accurately reflecting the company's financial status and operational results[80] - The company has committed to maintaining transparency and accuracy in its financial reporting, as stated by the management team[199] - There are no reported instances of non-operational fund occupation by controlling shareholders or related parties[200] Accounting Policies - The company has not reported any significant changes in its accounting policies or the scope of consolidation compared to the previous period[86] - The company’s accounting year runs from January 1 to December 31[106] - The company will account for the fair value of equity investments held prior to the acquisition date as part of the initial investment cost, with any fair value changes recognized in the current period's investment income[110] - The company will recognize costs related to mergers and acquisitions as they occur, with transaction costs directly attributable to equity transactions deducted from equity[111] - The company will separately present the interests of minority shareholders in the consolidated financial statements, including their share of net losses exceeding their initial equity[113]

证券代码：600285 证券简称：羚锐制药 公告编号：2023-044 号 河南羚锐制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （600285@lingrui.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 河南羚锐制药股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日发布 公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年 度经营成果、财务状况，公司计划于 2023 年 08 月 21 日下午 15:00-16:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 08 月 21 日 下午 15:00-16 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2023-023 河南羚锐制药股份有限公司 关于召开 2022 年度业绩说明会的公告 本次投资者说明会以视频录播结合网络互动召开，公司将针对 2022 年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 05 月 23 日下午 15:00-16:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 23 日(星期二)下午 15:00-16:30 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2023 年 05 月 16 日(星期二)至 05 月 22 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通 ...

Financial Performance - Net profit attributable to shareholders increased by 10.30% to ¥144,246,384.90[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 31.71% to ¥137,935,222.71, mainly due to an increase in operating income[6] - Operating revenue increased by 15.62% to ¥788,648,249.06[5] - Basic earnings per share rose by 9.70% to ¥0.260[5] - Diluted earnings per share increased by 10.92% to ¥0.254[5] - Net profit for the period reached ¥144,180,298.27, compared to ¥130,703,737.36 in the previous period, reflecting a growth of approximately 10.3%[28] - Total comprehensive income attributable to the parent company for Q1 2023 was ¥144,438,296.32, compared to ¥141,931,560.56 in Q1 2022, showing a slight increase of 3.6%[46] Assets and Liabilities - Total assets increased by 3.39% to ¥4,491,462,147.19 compared to the end of the previous year[2] - The company's total assets increased to ¥4,491,462,147.19 from ¥4,344,382,669.23, marking a rise of about 3.4%[27] - The equity attributable to shareholders of the parent company grew to ¥2,698,987,708.12, up from ¥2,550,918,961.13, which is an increase of approximately 5.8%[27] - The total liabilities as of Q1 2023 were ¥1,784,981,313.28, a slight decrease from ¥1,785,916,842.12 in Q1 2022[54] - The company recorded a total liability and equity of ¥4,491,462,147.19, consistent with the total assets, indicating a balanced financial position[27] Cash Flow - Net cash flow from operating activities decreased by 5.60% to ¥81,521,628.54[5] - Net cash generated from operating activities was ¥836,158,048.46 in Q1 2023, compared to ¥629,898,482.07 in Q1 2022, indicating a significant increase of 32.8%[57] - The net increase in cash and cash equivalents for Q1 2023 was ¥241,987,944.29, contrasting with a decrease of ¥47,538,320.80 in Q1 2022[49] - Operating cash inflow totaled CNY 873,767,046.56, an increase from CNY 668,624,954.82 in the previous period, reflecting a growth of approximately 30.7%[59] - Operating cash outflow amounted to CNY 792,245,418.02, compared to CNY 582,266,126.03, indicating an increase of about 36.0%[59] - Cash inflow from investment activities reached CNY 269,457,277.50, a decrease from CNY 280,069,462.48, showing a decline of approximately 2.2%[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,330[3] - The company repurchased and canceled 159,312 restricted stocks, adjusting the total number of granted restricted stocks to 13,211,288[23] Expenses - Total operating costs for Q1 2023 were ¥622,764,688.53, up 10.1% from ¥565,337,386.79 in Q1 2022[44] - Research and development expenses increased to ¥21,205,202.59 in Q1 2023, compared to ¥20,140,886.19 in Q1 2022, reflecting a growth of 5.3%[44] - Sales expenses for Q1 2023 amounted to ¥376,349,019.13, an increase of 14.5% from ¥328,590,129.99 in Q1 2022[44] - Cash paid to employees increased to CNY 77,976,112.17 from CNY 62,791,788.93, marking a rise of approximately 24.2%[59] - Taxes paid rose to CNY 146,557,715.10 from CNY 94,317,303.04, indicating an increase of around 55.4%[59] Other Financial Metrics - The weighted average return on equity decreased by 0.08 percentage points to 5.50%[2] - Interest income increased to ¥6,559,323.78 from ¥5,077,301.07, showing a growth of about 29.2%[28] - The company reported a financial expense of -¥5,819,501.33, compared to -¥3,642,842.09 in the previous period, indicating an increase in financial costs[28] - Other comprehensive income after tax for the period was ¥204,257.86, compared to ¥11,162,985.63 in the previous period, showing a significant decrease[28] - The company’s long-term equity investments remained stable at ¥71,690,947.15, slightly up from ¥71,652,345.36[26]